Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
|Articles|March 1, 2019
AJMC® in the Press, March 1, 2019
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Advertisement
An article from The American Journal of Managed Care®’s sister site The Center for Biosimilars® was highlighted by OBR Oncology’s daily newsfeed. The article, “
Advertisement
Related to this article
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.
Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Lung Cancer Progress Drives Down US Cancer Death Rates
3
Contributor: Congress Can Bring Mental Health Care to the 21st Century
4
Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care
5